In addition to allowing identification of target organ toxicities, the aim of non-clinical safety studies is to yield data that will provide the basis for estimating the safe starting dose for clinical trials.
ESTIMATION OF SAFE STARTING DOSE
AND SAFETY ASSESSMENT AND RISK–BENEFIT ANALYSIS
In
addition to allowing identification of target organ toxicities, the aim of
non-clinical safety studies is to yield data that will provide the basis for
estimating the safe starting dose for clinical trials. The data should also
inform the choice of dose regimen and dose esca-lations in early phase clinical
trials and form the basis of risk–benefit analyses for clinical trial
protocols.
Traditionally,
selection of doses for first-into-human clinical trials has been based on the
no observed effect level (NOEL) or no observed adverse effect level (NOAEL)
and, where appropriate, the systemic exposures achieved at these levels. A
figure for the maximum human starting dose can then be assessed using
allometric scaling and the applica-tion of safety factors, as considered
appropriate by the Sponsor and Investigator. There are currently no
international guidelines on the estimation of the safe starting doses for a
clinical trial; however, the FDA has issued draft guidance on this subject
(FDA, 2002). The guideline describes an algorithm for deriving the maximum
recommended starting dose for first-into-human clinical trials, recommending
that a standard procedure is used to select this dose. The algorithm utilises
the NOAEL observed in the most sensitive species and converts this to a human
equiv-alent dose, using a conversion factor based on body surface area, or,
where more appropriate, using scal-ing on a mg/kg basis. Safety factors are
then applied to obtain the maximum starting dose.
There
is no equivalent European regulatory guid-ance on setting the starting dose;
however, accord-ing to the ICH GCP guideline (EMEA, 1995) the route of
administration, dose levels and dosage regi-men proposed by the Sponsor and
Investigator should be justified in the protocol. Sometimes the justifica-tions
offered in the protocol are brief, but in any case the proposed dose and
regimen should be thoroughly examined in the risk–benefit analysis that is
included in the Investigational Medicinal Product Dossier that is submitted to
the regulatory authorities as part of the clinical trial application in European
Member States (European Commission, 2005).
In
summary, the risk–benefit analysis examines the proposed clinical trial
protocol, together with the main findings of the non-clinical safety studies
and assesses whether the risks associated with the trial are acceptable. The
European guidance on clinical trial applications (European Commission, 2005)
indicates that the risk– benefit analysis should be a brief, integrated summary
that critically analyses the non-clinical and clinical data in relation to the
proposed trial. The author(s) of the analysis should use the relevant
pharmacology, toxicology and kinetic results as the basis of extrap-olation to
indicate possible risks in humans. Where appropriate, the safety margins should
be discussed in terms of relative systemic exposure to the investi-gational
product rather than in terms of applied dose. The analysis should include
discussion of the clinical relevance of any findings from non-clinical and
clini-cal studies, together with recommendations for further monitoring of
effects and safety in clinical trials.
Related Topics
TH 2019 - 2023 pharmacy180.com; Developed by Therithal info.